Chinese Journal of Integrative Medicine

, Volume 24, Issue 11, pp 867–872 | Cite as

Chinese Medicine Yishen Jiangu Granules (益肾健骨颗粒) on Aromatase Inhibitor-Associated Musculoskeletal Symptoms

  • Xing Zhang
  • Nan Peng
  • Ming-wei Yu
  • Gan-lin Zhang
  • Xu Sun
  • Guo-wang Yang
  • Chen Li
  • Lin Yang
  • Xiao-min WangEmail author
Clinical Experience



To assess the effectiveness of Yishen Jiangu Granules (益肾健骨颗粒, YSJGG) on aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).


A single-arm, open-label study was conducted in 34 postmenopausal women with breast cancer who experienced AIMSS. Patients were treated with YSJGG for 12 weeks (12.4 g orally twice daily). The primary outcome was a change in the mean worst pain score of Brief Pain Inventory-Short Form (BPI-SF) over 12 weeks, and the second outcomes included changes in pain severity and pain-related interference of BPI-SF and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Modified Score for the Assessment of Chronic Rheumatoid Affections of the Hands (M-SACRAH), the Functional Assessment of Cancer Therapy-Breast (FACT-B), bone mineral density (BMD) and blood indices such as calcium (Ca), phosphate (P), and alkaline phosphatase (ALP).


Of 37 women recruited, 30 initiated the therapy and 24 were evaluable at 12 weeks. The primary outcome (BPI-SF worst pain scores) achieved a 2.17-point reduction compared with baseline (5.75±1.87 vs 3.58±2.15, P<0.01). There were reductions in pain severity (decreased 1.65, P<0.01) and pain-related interference (decreased 2.55, P<0.01). The changes in WOMAC and M-SACRAH scores were similar to BPI-SF (P<0.05). In the FACT-B, only physical well-being and functional well-being were improved compared with baseline (P<0.05). No clinical differences were found in BMD, Ca, P and ALP.


YSJGG is an effective and well-tolerated agent to reduce AIMSS.


aromatase inhibitors breast cancer musculoskeletal symptoms Chinese medicine Yishen Jiangu Granules 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Clemons M, Coleman RE, Verma S. Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard? Cancer Treat Rev 2004;30:325–332.CrossRefPubMedGoogle Scholar
  2. 2.
    Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007;25:3877–3883.CrossRefPubMedGoogle Scholar
  3. 3.
    Gaillard S, Stearns V. Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res 2011;13:205.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Lin C, Lin X, Yang J. An observation on combined use of chemotherapy and traditional Chinese medicine to relieve cancer pain. J Tradit Chin Med 1996;16:267–269.PubMedGoogle Scholar
  5. 5.
    Jiang S, Liu H, Liu Z, Liu N, Liu R, Kang Y, et al. Adjuvant effects of fermented red ginseng extract on advanced nonsmall cell lung cancer patients treated with chemotherapy. Chin J Integr Med 2017;3:331–337.CrossRefGoogle Scholar
  6. 6.
    Zhou D, ed. Oncology of traditional Chinese medicine. Beijing: China Press of Traditional Chinese Medicine; 2011:16–39.Google Scholar
  7. 7.
    Sun G, Tong Y, Chen W, eds. Basic theory of traditional Chinese medicine. Beijng: China Press of Traditional Chinese Medicine; 2002:72–98.Google Scholar
  8. 8.
    Peng N, Zhang Y, Ma C, Yu M, Yang G, Fu Q. Effects of the traditional Chinese medicine Yi Shen Jian Gu Granules on aromatase inhibitor-associated musculoskeletal symptoms: a study protocol for a multicenter, randomized, controlled clinical trial. Trials 2014;15:171.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2014;25 Suppl 3:iii124–137.Google Scholar
  10. 10.
    Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129–138.PubMedGoogle Scholar
  11. 11.
    Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833–1840.PubMedGoogle Scholar
  12. 12.
    Sautner J, Andel I, Rintelen B, Leeb BF. Development of the M–SACRAH, a modified, shortened version of SACRAH (Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands). Rheumatology (Oxford) 2004;43:1409–1413.CrossRefGoogle Scholar
  13. 13.
    Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy–Breast Quality-of-Life Instrument. J Clin Oncol 1997;15:974–986.CrossRefPubMedGoogle Scholar
  14. 14.
    Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105–121.CrossRefPubMedGoogle Scholar
  15. 15.
    Niravath P. Aromatase inhibitor-induced arthralgia: a review. Ann Oncol 2013;24:1443–1449.CrossRefPubMedGoogle Scholar
  16. 16.
    Zhong L, Zhang W, Hua Y, Ji P, Yao W, Li J. et al. Metabolomic evaluation for anti-inflammatory effect of volatile oils from different preparations of Angelicae Sinensis Radix. China J Chin Mater Med (Chin) 2016;41:2061–2069.Google Scholar
  17. 17.
    Yang Q, Yang L, Xiong A, Lu L, Wang R, Wang Z. Metabolomics study of anti-inflammatory action of Radix Paeoniae Rubra and Radix Paeoniae Alba by ultraperformance liquid chromatography–mass spectrometry. China J Chin Mater Med (Chin) 2011;36:694–697.Google Scholar
  18. 18.
    Huang J, Fang M, Li Y, Ma Y, Cai X. Analgesic effect of Corydalis yanhusuo in a rat model of trigeminal neuropathic pain. J Nanfang Med Univ (Chin) 2010;30:2161–2164.Google Scholar
  19. 19.
    Sestak I, Sapunar F, Cuzick J. Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. J Clin Oncol 2009;27:4961–4965.CrossRefPubMedGoogle Scholar
  20. 20.
    Hershman DL, Unger JM, Crew KD, Awad D, Dakhil SR, Gralow J, et al. Randomized multicenter placebo-controlled trial of Omega–3 fatty acids for the control of aromatase inhibitor-induced musculoskeletal pain: SWOG S0927. J Clin Oncol 2015;33:1910–1917.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine 2018

Authors and Affiliations

  • Xing Zhang
    • 1
    • 2
  • Nan Peng
    • 1
  • Ming-wei Yu
    • 1
  • Gan-lin Zhang
    • 1
  • Xu Sun
    • 1
  • Guo-wang Yang
    • 1
  • Chen Li
    • 1
  • Lin Yang
    • 1
  • Xiao-min Wang
    • 1
    Email author
  1. 1.Department of OncologyBeijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical UniversityBeijingChina
  2. 2.Graduate SchoolBeijing University of Chinese MedicineBeijingChina

Personalised recommendations